Stanford Starts Seattle Genetics (SGEN) at Hold
More News related to SGEN
- Seattle Genetics to Present at Upcoming Investor Conferences
- CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
- Seattle Genetics to Present at the Oppenheimer Healthcare Conference
- Seattle Genetics Presents on SGN-70 at American College of Rheumatology Meeting
- Oppenheimer Upgrades Seattle Genetics (SGEN) to Outperform
More News related to New Coverage
- Friedman Billings Starts Aircastle (AYR) at Underperform
- Friedman Billings Starts Netflix (NFLX) at Market Perform
- Credit Suisse Starts 3PAR (PAR) at Neutral
- Credit Suisse Starts Netezza (NZ) at Neutral
- FBR Starts Amazon.com (AMZN) at Market Perform
Stanford Group initiates coverage on Seattle Genetics (Nasdaq: SGEN) with a Hold rating.
Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease.
Related Categories
New CoverageStocks Mentioned
-0.99Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
